ACTIVATION OF RAF/MEK/ERK AND PI3K/AKT/mTOR PATHWAYS
IN PITUITARY ADENOMAS AND THEIR EFFECTS ON DOWNSTREAM
EFFECTORS

Dworakowska D*1,2, Wlodek E*1, Leontiou CA1, Igreja S1, Cakir M1,2, Teng M1, Prodromou N1, Góth
M1, Grozinsky-Glasberg S1,5, Gueorguiev M1, Kola B1, Korbonits M1 and Grossman AB1

1Centre for Endocrinology, Barts and the London School of Medicine, EC1M 6BQ, UK; 2Department of
Endocrinology and Internal Medicine, Medical University of Gdañsk, 80-211, 3 Sklodowskiej-Curie Str.,
Poland; 3Meram School of Medicine, Division of Endocrinology and Metabolism, Selcuk University,
Meram, Konya, Turkey; 4Internal Medicine, National Health Center, Budapest, Hungary; 5Institute of
Endocrinology and Metabolism, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, 49100, Israel

SHORT TITLE: Raf/MEK/ERK and PI3K/Akt/mTOR in pituitary adenomas

KEY WORDS: MEK1/2, ERK1/2, p38MAPK, mTOR, TSC2, p70S6K, c-MYC, CYCLIN D1, pituitary
adenoma, senescence, IL-6

Address proofs and all correspondence to:
Ashley Grossman BA BSc MD FRCP FMedSci
Professor of Neuroendocrinology
Centre for Endocrinology, Barts and the London School of Medicine
Postal Address:
Dept. of Endocrinology
5th Floor King George V Building
St Bartholomew's Hospital
West Smithfield
London EC1A 7BE
Tel: +44-20 76018343
Fax: +44-20 76018505
Email: a.b.grossman@qmul.ac.uk

* To be considered as joint first authors
ABSTRACT

Raf/MEK/ERK and PI3K/Akt/mTOR cascades are key signalling pathways interacting with each other to regulate cell growth and tumourigenesis. We have previously shown B-Raf and Akt over-expression and/or over-activation in pituitary adenomas. The aim of this study was to assess the expression of their downstream components (MEK1/2, ERK1/2, mTOR, TSC2, p70S6K) and effectors (c-MYC and CYCLIN D1).

We studied tissue from 16 non-functioning pituitary adenomas (NFPAs), 6 GH-omas, 6 PRL-omas and 6 ACTH-omas, all collected at transsphenoidal surgery; 16 normal autopsy pituitaries were used as controls. The expression of phospho- and total protein was assessed with Western immunoblotting, and the mRNA expression with quantitative RT-PCR.

The expression of pSer217/221 MEK1/2 and pThr183 ERK1/2 (but not total MEK1/2 or ERK1/2) was significantly higher in all tumour sub-types in comparison to normal pituitaries. There was no difference in the expression of phosphorylated/total mTOR, TSC2 or p70S6K between pituitary adenomas and controls. Neither c-MYC phosphorylation at Ser 62 nor total c-MYC was changed in the tumours. However, c-MYC phosphorylation at Thr58/Ser62 (a response target for Akt) was decreased in all tumour types. CYCLIN D1 expression was higher only in NFPAs. The mRNA expression of MEKI, MEK2, ERK1, ERK2, c-MYC and CCND1 was similar in all groups.

Our data indicate that in pituitary adenomas both the Raf/MEK/ERK and PI3K/Akt/mTOR pathways are up-regulated in their initial cascade, implicating a pro-proliferative signal derangement upstream to their point of convergence. However, we speculate that other processes, such as senescence, attenuate the changes downstream in these benign tumours.
INTRODUCTION

Pituitary tumours are common neoplasms, with a reported overall prevalence of 16.7% in the general population, 14.4% in autopsy studies and 22.5% in radiological studies (Ezzat, et al. 2004). These tumours are almost always benign, but cause significant morbidity through mass effects and/or the inappropriate secretion of pituitary hormones (Ezzat et al. 2004). Despite intensive study, the molecular pathogenesis of the majority of sporadic pituitary adenomas remains unclear (Asa and Ezzat 2002; Melmed 2008). There are several genetic syndromes associated with pituitary tumours, but abnormalities in the genes mutated in these syndromes are rarely abnormal in sporadic tumours (Beckers and Daly 2007; Boikos and Stratakis 2007; Horvath and Stratakis 2008; Karhu and Aaltonen 2007; Leontiou, et al. 2008). There are also a number of tumour suppressor genes which are inactivated in sporadic tumours, often by promoter methylation, but no single causal agent or mutation has been identified (Dworakowska and Grossman 2009).

Two major signalling pathways responsible for regulating cell growth and proliferation, downstream of growth factor receptors, are the phosphatidylinositol 3-kinase (PI3K)/Akt and Raf/mitogen-activated protein kinase (MAPK) pathways (McCubrey, et al. 2007). These have been shown to be over-active in many human tumours (Adjei and Hidalgo 2005; Roberts and Der 2007). It has been reported that Akt is over-expressed and over-activated in non-functioning pituitary adenomas (NFPAs) (Musat, et al. 2005), and there is recent evidence that B-Raf, an upstream regulator of the MAPK cascade, is also over-expressed predominantly in NFPAs (Ewing, et al. 2007). Such activation may account for the changes in cell-cycle components which are a frequent characteristic of pituitary tumours, especially p27 (Lidhar, et al. 1999; Lloyd, et al. 1997). In addition, we have shown that somatostatin analogues, which cause tumour...
regression in certain types of pituitary adenoma, down-regulate the MAPK pathway in pituitary
tumours (Hubina, et al. 2006). However, it has been unclear as to whether the changed
expression of the upstream components of these two converging pathways is associated with
downstream modulation of their subsequent effectors.

Raf/MEK/ERK is a hierarchical cascade, originating at the cell membrane with receptors
for mitogens or growth factors, which recruit, via adapter proteins and exchange factors, the
small guanosine triphosphatase (GTPase) Ras (Adjei and Hidalgo 2005). Ras then activates Raf
(MAPK kinase kinase, MAPKKK), which in turn activates mitogen-activated protein kinase
kinase (MAPKK; MEK1/2): MEK1/2 proteins are dual-specificity kinases containing two
consensus kinase motifs, one motif being involved in phosphorylation of serine/threonine
residues while the other is involved in phosphorylation of tyrosine residues. Two MEK
homologues, MEK1 and MEK2, are activated through phosphorylation of two serine residues at
positions 217 and 221 by Raf-like molecules, and then MEK1/2 sequentially phosphorylate
ERK1 and ERK2 at two sites, Tyr185 followed by Thr183 (Haystead, et al. 1992). ERK1/2 in
turn phosphorylates and activates ribosomal S6 kinase and transcription factors such as c-MYC,
Elk1, c-Fos or CYCLIN D1 (Terada, et al. 1999a; Terada, et al. 1999b), resulting in the
modulation of genes associated with proliferation (Guan 1994) and leading to cell transformation
(Joneson and Bar-Sagi 1997). ERK1 and 2 activate CYCLIN D1 promoter activity and CYCLIN
D1 expression, whereas p38MAPK works in an opposing manner, inhibiting CYCLIN D1
transcription and expression (Lavoie, et al. 1996).

In terms of the PI3K/Akt/mTOR pathway, PI3K is activated as a result of the ligand-
dependent activation of tyrosine kinase receptors, G-protein-coupled receptors, or integrins.
Receptor-independent activation of PI3K can also occur in cells expressing constitutively-active
Ras protein (Kauffmann-Zeh, et al. 1997; Rodriguez-Viciana, et al. 1997). The best-characterised phosphorylation target of PI3K is Akt (protein kinase B), resulting in the phosphorylation of a host of other proteins that affect cell growth, cell cycle entry, and cell survival. Akt phosphorylation at Thr308 and Ser473 activates a serine-threonine kinase mTOR (mammalian Target Of Rapamycin) at Ser2448, which activates further 40S ribosomal protein S6 kinase (p70S6K) at Thr229 and Thr389 (Volarevic and Thomas 2001) and inactivates 4E-binding protein (4E-BP1). The tuberous sclerosis complex (TSC) – which mediates between PI3K/Akt and mTOR – is germline mutated in tuberous sclerosis, and there is evidence that neuroendocrine and pituitary tumours are a feature of this disease (Dworakowska and Grossman 2008). Mitogenic stimuli activating Akt phosphorylate TSC2 at Ser939 and Thr1462. This phosphorylation destabilises TSC2, inhibits the formation of the TSC1/2 complex, and leads to an increase in mTOR activity (Inoki, et al. 2002). Changes in 4E-BP1 lead to the initiation of translation of mRNA for c-MYC or CYCLIN D1 through its association with eIF-4E (Rosenwald, et al. 1995; Sonenberg and Gingras 1998), while Akt also activates CYCLIN D1 indirectly via glycogen synthase kinase-3 (GSK-3β) (Diehl, et al. 1998; Onofri, et al. 2006). There is also further evidence that these two pathways interact, eg, ERK1/2 indirectly activates mTOR by phosphorylation of TSC2 at Ser669. Thus, both pathways are involved in the regulation of c-MYC and CYCLIN D1 transcription. ERK1/2 also directly activates phosphorylation of c-MYC protein at Ser62 leading to its accumulation, whereas Akt decreases phosphorylation (via GSK-3β) at Thr58 which diminishes c-MYC degradation (Sears, et al. 2000).

The aim of this study was to investigate in more detail the status of the intervening components of Raf/MEK/ERK and PI3K/Akt/mTOR pathways as well as their two principal
targets - c-MYC and CYCLIN D1. In different types of human pituitary adenomas and normal pituitary we assessed the protein expression of phosphorylated/total MEK1/2, ERK1/2, p38MAPK, TSC2, mTOR, p70S6K, c-MYC and CYCLIN D1. In addition, we performed a quantitative analysis of mRNA expression of all of the components which had show alterations at the protein level (MEK1, MEK2, ERK1, ERK2, c-MYC and CCND1).

MATERIAL AND METHODS

Tissues

We studied tissue from 50 human pituitaries (Table 1) including 16 NFPAs, 6 somatotrophinomas (GH-omas), 6 prolactinomas (PRL-omas) and 6 corticotrophinomas (ACTH-oma), removed at transsphenoidal surgery and immediately ‘flash-frozen’ and stored at -80°C. Sixteen normal pituitary samples were used as a control group. These were collected at autopsy (which was performed within 24 hours of death from non-endocrine disease), ‘flash-frozen’ and stored at -80°C. The tumour study group consisted of 18 men (53%) and 16 women (47%), with a mean age of 58.3 years (age range 19-77 years). The controls consisted of 13 men (81%) and 3 women (19%), with a mean age of 64.7 years (age range 42-77 years). All patients gave written informed consent for the protocol, which was approved by the local Institutional Review Board (IRB). The autopsy collection was also approved by the relevant local IRB.

Protein extraction and Western blot analysis

Whole lysates were prepared from 50–250µg frozen fresh human pituitary tissue by homogenisation in 500 µl ice-cold cell lysis buffer with added 1mM PMSF, followed by a brief
sonication and centrifugation at 12,000g for 20 min at 4°C. The supernatant was saved and stored at -80°C. Protein yield was quantified using the BCA protein assay kit (Pierce-Perbio, Cramlington, UK). Fifty µg of total protein lysate were denatured in SDS sample buffer, separated by electrophoresis on a SDS–PAGE gel (10%) and transferred to a nitrocellulose membrane (Immobilon-P; pore size 0.45 mm; Millipore, Watford, Herts, UK). The membrane was subsequently incubated with the primary antibody in 0.1% or 5% bovine serum albumin, or in 5% non-fat dry milk in Tris-buffered saline/Tween 20 overnight at 4°C (Table 2). After 6 washes in Tris-buffered saline/Tween 20, the membranes were incubated with the secondary antibody for 90 mins. Immunodetection was performed using the Odyssey infrared imaging system (LI-COR Biosciences, Cambridge, UK). Each membrane was incubated and double-stained with two primary antibodies (phospho-protein and β-actin or total protein and β-actin). Cross-detection between analysed protein and β-actin was avoided by using different species-raised against primary antibodies. To assess expression of each protein we have constructed a set consisting of 3 membranes (15 wells), including all sample types (4 normal pituitaries, 2 PRL-omas, 2 ACTH-omas, 2 GH-omas and 4 NFPAs). One well was reserved for the size marker. The optical density of the appropriately sized bands was measured using the Odyssey molecular imaging software (LI-COR Biosciences).

The expression of phospho-mTOR, phospho-TSC2, phospho-p70S6K, phospho-ERK1/2, phospho-MEK1/2, phospho-c-MYC and phospho-p38MAPK was normalised to β-actin from the corresponding membrane and was calculated as a ratio of phospho-peptide/β-actin. The expression of total-mTOR, total-TSC2, total-p70S6K, total-ERK1/2, total-MEK1/2, total-c-MYC, total-p38MAPK and CYCLIN D1 was normalised to β-actin from the corresponding membrane and was calculated as a ratio of total/β-actin. The relative expression of each
phospho-protein was calculated as well as the proportion of phospho/total protein. All results normalised to β-actin were compared between subgroups of pituitary tumours, and are shown as % of control.

mRNA extraction and ‘real-time’ PCR

Total RNA from tissue was extracted using an RNeasy Mini Kit (Qiagen, Hilden, Germany) and the protocol was followed according to the manufacturers’ instructions. A DNase treatment step was performed to limit contamination of the total RNA with genomic DNA. 1 µg of total RNA was reverse-transcribed (RT) in a 25 µl reaction using 5 µl 5x first strand buffer (Invitrogen, Carlsbad, Canada), 100mM DTT (Invitrogen), 20 mM of deoxynucleotide triphosphate (dNTPs) (Promega, Madison, USA), 20 µg/µl random hexamer primers (Promega), MMW-RT (Invitrogen) and 40 U/µl RNase inhibitor (Promega). Thermal cycling conditions were as follows: 26°C for 10 minutes, 37°C for 60 minutes and 92°C for 10 minutes. cDNA was amplified by real-time PCR using TaqMan® Universal Master Mix (Applied Biosystems, New Jersey, USA), 20x assay primers and their respective assay ID for human MEK1 Hs00983256_g1, MEK2 Hs00360961_m1, MAPK1 (encoding for ERK2) Hs00177066+m1, MAPK3 (encoding for ERK1) Hs00385075_m1, CCND1 Hs00277039_m1, c-MYC Hs0015348_m1 and the β-actin Vic-MGB probe 4326315E. cDNA was amplified in a 7900HT Taqman machine (Applied Biosystems). All data were expressed in relation to β-actin and then calculated relative to the percentage of control.

Statistical analysis
Statistical analysis was performed with StatsDirect software (Buchan I; Addison Wesley Longman, Cambridge, UK). The data were noted to be non-normally distributed. Statistical analysis was performed with the use of the Kruskal-Wallis test followed by the Conover-Inman comparison, the Mann-Whitney test and the Spearman correlation test. Statistical significance was defined at P<0.05 and all data are shown as means ± S.E.M.

RESULTS

Western blotting

The expression of pSer217/221 MEK1/2 (Figure 1 A), but not total MEK1/2 (Figure 1 B), was significantly higher in PRL-omas (277±27%, P<0.001), ACTH-omas (287±14%, P<0.001), GH-omas (175±39%, P=0.009) and NFPAs (281±15%, P<0.001) in comparison to normal pituitaries. Furthermore, the ratio between pSer217/221 MEK1/2 and total MEK1/2 was significantly higher in all groups of pituitary tumours in comparison to normal pituitaries (271±13% for PRL-omas, P=0.001; 227±30% for ACTH-omas, P<0.001; 187±15% for GH-omas; P=0.01 and 371±45% for NFPAs; P<0.001) (Figure 1C).

The expression of pThr183 ERK1/2 (Figure 2 A), but not total ERK1/2 (Figure 2 B), was significantly higher in PRL-omas (174±16%, P=0.01), ACTH-omas (231±46%, P<0.001), GH-omas (184±38%, P=0.01) and NFPAs (317±38%, P<0.001) in comparison to normal pituitaries. Furthermore, the ratio between pThr183 ERK1/2 and total ERK1/2 was also significantly higher in all groups of pituitary tumours in comparison to normal pituitaries (274±13% for PRL-omas, P<0.001; 290±30% for ACTH-omas, P<0.001; 198±15% for GH-omas; P=0.01 and 214±12% for NFPAs; P<0.001) (Figure 2 C).
There was no difference in either total mTOR (P=0.46) or its phospho-derivative Ser2448 (P=0.25); in total TSC2 (P=0.78) or its derivatives Ser939-TSC2 (P=0.88) or Thr1462-TSC2 (P=0.84); or in total p70S6K (P=0.72) or its phospho-derivative Thr389 (P=0.47) between any type of pituitary adenoma and normal pituitary.

There was no difference in the expression of Ser62 c-MYC between pituitary adenomas and normal pituitary (P=0.75). However, the expression of c-MYC doubly-phosphorylated at Ser62/Thr58 (Figure 3A), but not total c-MYC (Figure 3 B), was significantly decreased in all types of adenoma in comparison to normal pituitary (45±4% for PRL-omas, P=0.01; 40±6% for ACTH-omas, P=0.01; 42±6% for GH-omas, P=0.04 and 54±9% for NFPAs, P=0.06). Furthermore, the ratio between c-MYC doubly-phosphorylated at Ser62/Thr58 and total c-MYC was also significantly lower in all secretory groups of pituitary tumours in comparison to normal pituitaries, and tending towards significance in the NFPAs (37±9% for PRL-omas, P=0.01; 33±12% for ACTH-omas, P=0.01; 35±11% for GH-omas; P=0.01 and 56±26% for NFPAs, P=0.09) (Figure 3 C).

A significant increase in CYCLIN D1 expression was observed in NFPAs compared to normal controls (136%±10, P=0.01), but not in any of the other adenoma groups (Figure 4). There was no difference in the amount of pThr180/Tyr182 p38MAPK between the normal or abnormal tissue (P=0.17; data not shown).

Representative Western blots are shown for pMEK1/2, tMEK1/2 and β-actin (Figure 5 A), pERK1/2, tERK1/2 and β-actin (Figure 5 B), doubly-phosphorylated c-MYC, total c-MYC and β-actin (Figure 5 C), and CYCLIN D1 and β-actin expression (Figure 5 D), in normal pituitaries, PRL-omas, ACTH-omas, GH-omas and NFPAs in Figure 5.
Quantitative RT-PCR

Quantification of mRNA showed similar expression for MEK1, MEK2, ERK1, ERK2, c-MYC and CCND1 in all tissue groups (P=0.78 for MEK1; P=0.46 for MEK2; P=0.73 for ERK1; P=0.23 for ERK2; P=0.59 for c-MYC and P=0.62 for CCND1, respectively). Representative results for mRNA of analysed genes normalized to β-actin in controls and NFPAs are shown in Figure 6. There was no correlation between the amount of protein product assessed by Western blotting and mRNA assessed by RT-PCR for any of the molecular species (P=0.10 for ERK1; P=0.41 for ERK2; P=0.54 for c-MYC and P=0.84 for CCND1, respectively).

DISCUSSION

The Raf/MEK/ERK and PI3K/PTEN/Akt pathways diverge from common growth factor receptors on the cell surface, modulating phosphorylation of many downstream targets involved in cell survival, proliferation, and in some cases in malignant transformation. In this study of human pituitary adenomas, we demonstrate that our previously-reported over-expression of B-Raf (MAPKKK) was associated with increased phosphorylation, and hence activation, of its immediate downstream targets MEK1/2 (MAPKK) and ERK1/2 (MAPK) in all adenoma subtypes. However, we were only able to show a small increase in CYCLIN D1 expression, in NFPAs alone, and we did not find the increase in pSer62 c-MYC expression that would be expected with activation of the MAPK pathway. In terms of the PI3K/Akt pathway, we did not see any increased phosphorylation of TSC2 by Akt, nor the anticipated changes secondary to Akt.
in mTOR or p70S6K. Two N-terminal phosphorylation sites in c-MYC, Thr58 and Ser62, are known to be regulated by mitogen stimulation. Phosphorylation of Ser62 mediated by ERK1/2 is required for Ras-induced stabilisation of c-MYC, but conversely, phosphorylation of Thr58, mediated by GSK-3β (DePaoli-Roach 1984) but dependent on the prior phosphorylation of Ser62, is associated with degradation of c-MYC (Cross, et al. 1995; Sears et al. 2000). In this study we found decreased c-MYC phosphorylation at Thr62/Ser58 concordant with previously described Akt over-activation in pituitary adenomas, an effect thought to occur via Akt-mediated phosphorylation of GSK-3β. We were unable to check the status of TSC2 phosphorylated at the site activated by ERK1/2, Ser669, since there is no commercially available antibody to detect this site.

In a very recent animal study performed in a mouse model, which spontaneously develops TSH-secreting pituitary adenomas (Lu, et al. 2008), Akt and its downstream effectors mTOR and p70S6K were activated and contributed to increased cell proliferation and pituitary growth. In addition, activation of Akt led to decreased apoptosis by inhibiting pro-apoptotic activity of Bcl-2-associated death promoter, further contributing to the aberrant cell proliferation (Lu et al. 2008). In our study we did not show any alteration in mTOR and p70S6K status in different types of pituitary adenomas, although the very rare human TSH-omas were not included in this analysis.

It is recognised that ligand-dependent or mutational activation of receptor tyrosine kinase (RTKs), or mutational activation of pathway intermediates such as RAS and BRAF, lead to activation of ERK signalling with demonstrably high intracellular levels of pERK (Cobb and Goldsmith 1995; Lewis, et al. 1998). However, it has been suggested that expression of pERK
might sometimes be a poor measure of activation of ERK pathway signalling and not necessarily reflect substrate flux through this pathway, although this is a common assumption (Pratilas, et al. 2009). Nevertheless, the present data, together with previous studies, do suggest that the two major signalling pathways are likely to be over-active in pituitary tumours, and that therefore the fundamental change in pituitary adenoma cell status occurs either at, or upstream to, the point of convergence of these two pathways; this would be at the level of growth factor receptor(s), or their related control mechanisms. Indeed, a recent study has demonstrated that the membrane anchor E-cadherin is detached from the membrane of adenoma cells compared to normal pituitary (Elston, et al. 2009), suggesting that membrane changes and/or matrix-related events are a major feature of such tumours. Our results are compatible with the concept that they may be driving the process rather than occurring in response to cytoplasmic or nuclear signals.

Furthermore, this may be therapeutically important as growth factor receptors signal through tyrosine receptor kinases (TRKs), and such TRKs may be blocked by small-molecule TRK inhibitors (TKIs). It is possible that the TKIs may be of value in the treatment of recurrent or resistant pituitary tumours in the future.

Our findings on CYCLIN D1, which is regulated by both ERK1/2 and Akt pathways, are particularly interesting. CYCLIN D1 is a proto-oncogene (11q13) which acts in the pRb/p16/CDK4 pathway on G1-S progression of the cell cycle. \textit{CCND1} gene amplification (Hibberts, et al. 1999) and polymorphisms (Gazioglu, et al. 2007), and enhanced nuclear (Gazioglu et al. 2007; Jordan, et al. 2000) and/or cytoplasmic (Gazioglu et al. 2007; Hibberts et al. 1999; Jordan et al. 2000) accumulation, have been described in sporadic pituitary adenomas, especially in NFPAs (Hibberts et al. 1999; Jordan et al. 2000). Over-expression of CYCLIN D1 in NFPAs in comparison to other tumour types, as observed in our study, is essentially in
agreement with the study by Hibberts at al. where CYCLIN D1 was found to be specifically over-expressed in NFPAs in comparison to somatotrophinomas (Hibberts et al. 1999). However, the fact that in some cases of pituitary adenomas CYCLIN D1 over-expression occurred in the absence of \textit{CCND1} allelic imbalance suggested that additional mechanisms responsible for deregulated CYCLIN D1 expression are involved in human pituitary tumourigenesis (Hibberts et al. 1999). The mitogen-dependent induction of CYCLIN D1 expression is one of the earliest cell cycle-related events to occur during the G0/G1 to S-phase transition (Lavoie et al. 1996). Activation of the Raf/MEK/ERK cascade has been shown to be sufficient to induce CYCLIN D1 promoter activity and CYCLIN D1 expression, even in the absence of growth factors. In contrast, the p38MAPK cascade showed an opposite effect on the regulation of CYCLIN D1 expression (Lavoie et al. 1996). Based on Western blot analysis, we confirmed previous reports of CYCLIN D1 over-expression in NFPAs, but the increase was slight, was not seen in other tumour sub-types, and was not associated with any change in \textit{CCND1} mRNA. We speculated that the lack of change in transcription might be secondary to changes in p38MAPK, which decreases CYCLIN D1 transcription, but we did not see any changes in either p38MAPK activation or in the total amount of this protein.

Our results therefore demonstrate that while there is indeed evidence for over-activation of both signalling pathways, their effects are to a major extent attenuated downstream. This suggests that, in these benign tumours, overdrive of the signalling pathways is blunted by protective anti-tumour mechanisms (Aoki, et al. 2007) (Chesnokova, et al. 2008). One such mechanism is the recently–described process of senescence, particularly oncogene-induced senescence (OIS), whereby early neoplastic cells are eliminated from the proliferative pool. High pituitary p21 levels have been shown to promote senescence and restrain pituitary tumour
growth, particularly in somatotroph tumours, and may underlie the failure of invariably benign pituitary tumours to progress to true malignancy (Chesnokova et al. 2008). In addition, the pleiotropic cytokine interleukin-6 (IL-6) has been demonstrated to mediate senescence in a cell-autonomous, ie, non-paracrine, mode, and this is compatible with previous data that pituitary adenomas specifically immunostain for IL-6 (Jones, et al. 1994; Tsagarakis, et al. 1992).

In conclusion, in this study we describe over-activation of the downstream kinases to B-Raf in pituitary adenomas, as well as a slight increase in CYCLIN D1 in non-functioning tumours, but no change in c-MYC phosphorylation and hence stabilisation by ERK1/2. In contrast, the PI3K/Akt pathway shows no increased activity in its major downstream TSC/mTOR components, but there was decreased phosphorylation and thus increased stabilisation of c-MYC by this pathway. We speculate that the causal agent(s) in sporadic pituitary tumourigenesis are upstream to the convergence of these two Ras-dependent pathways, and that induced senescence, possibly involving p21 and/or IL-6, is responsible for the benign nature of the great majority of such tumours.
DECLARATION OF INTEREST

We declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

FUNDING

Studies were supported by the CRC of St. Bartholomew's Hospital and by OTKA K68660.

ACKNOWLEDGEMENTS

Dorota Dworakowska would like to thank the Polish Science Foundation for a post-doctoral fellowship to Barts and the London School of Medicine, London, England. Mehtap Cakir was awarded a grant from The Society of Endocrinology and Metabolism of Turkey to study at the Centre for Endocrinology, Barts and The London School of Medicine and Dentistry, London.
B-Raf/MEK/ERK and PI3K/Akt/mTOR in pituitary adenomas

REFERENCES


Oncogene 26 3291-3310.


LEGENDS TO THE FIGURES

Figure 1. MEK1/2 expression in normal pituitaries and in pituitary adenomas. The phospho-MEK1/2 at Ser 217/221 normalized to β-actin and total-MEK1/2 was elevated in all types of pituitary adenomas (P<0.001 and P<0.001, respectively) (Figure 1 A and C). There was no difference in total-MEK1/2 expression between control and adenomas groups (P=0.48) (Figure 1 B). In order to all groups the results are shown as % of control for the average of pMEK1/2 and tMEK1/2, normalized to β-actin, and pMEK1/2 normalized to tMEK1/2. Error bars represent S.E.M. **P<0.05 vs control.

Figure 2. ERK1/2 expression in normal pituitaries and in pituitary adenomas. The phospho-ERK1/2 at Thr183 normalized to β-actin and total-ERK1/2 was elevated in all types of pituitary adenomas (P<0.001 and P<0.001, respectively) (Figure 2 A and C). There was no difference in total-ERK1/2 expression between control and adenomas groups (P=0.42) (Figure 2 B). In order to all groups the results are shown as % of control for the average of pERK1/2 and tERK, normalized to β-actin, and pERK1/2 normalized to tERK1/2. Error bars represent S.E.M. **P<0.05 vs control.

Figure 3. c-MYC expression in normal pituitaries and in pituitary adenomas. The phospho-c-MYC at Ser62/Thr58 normalized to β-actin and total-c-MYC was decreased in all types of pituitary adenomas (P=0.03 and P=0.02, respectively) (Figure 3 A and C). There was no difference in total c-MYC expression between control and adenomas groups (P=0.12) (Figure 3 B). In order to all groups the results are shown as % of control for the average of doubly-phosphorylated c-MYC and total c-MYC, normalized to β-actin, and doubly-phosphorylated c-MYC normalized to total c-MYC. Error bars represent S.E.M. **P<0.05 vs control.
Figure 4. CYCLIN D1 expression in normal pituitaries and in pituitary adenomas. CYCLIN D1 normalized to β-actin was elevated in non-functioning pituitary adenomas (P=0.01), but not in other types of adenomas. In order to all groups the results are shown as % of control for the average of CYCLIN D1 normalized to β-actin. Error bars represent S.E.M. **P<0.05 vs control.

Figure 5. Representative Western blots for: A - pMEK1/2, tMEK1/2 and β-actin expression in normal pituitaries (n=4), and PRL-omas, ACTH-omas, GH-omas and NFPAs (n=2 for each, n=3 for NFPAs); B - pERK1/2, tERK1/2 and β-actin expression in normal pituitaries (n=4), PRL-omas, ACTH-omas, GH-omas and NFPAs (n=2 for each, n=3 for NFPAs); C - doubly-phosphorylated c-MYC, total c-MYC and β-actin expression in normal pituitaries (n=4), PRL-omas, ACTH-omas, GH-omas and NFPAs (n=2 for each, n=3 for NFPAs); D - CYCLIN D1 and β-actin expression in normal pituitaries (n=4), PRL-omas, ACTH-omas, GH-omas and NFPAs (n=2 for each n=4 for NFPAs).

Figure 6. Representative mRNA expression for MEK1, MEK2, ERK1, ERK2, c-MYC and CCND1 in normal pituitaries and non-functioning pituitary adenomas. mRNA expression of MEK1, MEK2, ERK1, ERK2, c-MYC and CCND1 was similar between controls and NFPA, as revealed by RT-PCR studies. The average ratio of mRNA for each gene normalized to β-Actin was shown as % of control. Error bars represent S.E.M.
Table 1. Clinical details of patients included in the study

<table>
<thead>
<tr>
<th>Clinical diagnosis</th>
<th>Samples studied (tumour size)</th>
<th>Patient gender</th>
<th>Patient age (mean + range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NFPA</td>
<td>n=16 (15 macro, 1 micro)</td>
<td>4 F, 12 M</td>
<td>56 years (28-75)</td>
</tr>
<tr>
<td>GH-oma</td>
<td>n=6 (1 macro, 5 micro)</td>
<td>4 F, 2 M</td>
<td>48 years (31-64)</td>
</tr>
<tr>
<td>PRL-oma</td>
<td>n=6 (2 macro, 4 micro)</td>
<td>3 F, 3 M</td>
<td>33 years (19-46)</td>
</tr>
<tr>
<td>ACTH-oma</td>
<td>n=6 (2 macro, 4 micro)</td>
<td>5 F, 1 M</td>
<td>48.3 years (24-77)</td>
</tr>
<tr>
<td>All adenomas</td>
<td>n=34</td>
<td>16F, 18M</td>
<td>58.3 years (19-77)</td>
</tr>
<tr>
<td>Normal pituitary</td>
<td>n=16</td>
<td>3F, 13 M</td>
<td>64.7 years (42-77)</td>
</tr>
</tbody>
</table>
Table 2. Antibodies used for Western blotting in the current study

<table>
<thead>
<tr>
<th>Antibody name</th>
<th>Origin</th>
<th>Concentration</th>
<th>Source</th>
<th>Primary/secondary</th>
<th>Monoclonal/polyclonal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-phospho-MEK1/2 (Ser217/221)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signaling Technology, Hitchin, UK</td>
<td>primary</td>
<td>monoclonal</td>
</tr>
<tr>
<td>Anti-MEK1/2 (total)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signaling Technology</td>
<td>primary</td>
<td>monoclonal</td>
</tr>
<tr>
<td>Anti-phospho-ERK1/2 (Thr183)</td>
<td>rabbit</td>
<td>1:4 000</td>
<td>Promega Corporation, Madison, USA</td>
<td>primary</td>
<td>polyclonal</td>
</tr>
<tr>
<td>Anti-ERK1/2 (total)</td>
<td>rabbit</td>
<td>1:5 000</td>
<td>Promega</td>
<td>primary</td>
<td>polyclonal</td>
</tr>
<tr>
<td>Anti-phospho-c-myc (Ser62)</td>
<td>mouse</td>
<td>1:200</td>
<td>Spring Bioscience, Fremont, CA</td>
<td>primary</td>
<td>monoclonal</td>
</tr>
<tr>
<td>Anti-phospho-c-myc (Thr58/Ser62)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signaling Technology</td>
<td>primary</td>
<td>polyclonal</td>
</tr>
<tr>
<td>Anti-c-myc (total)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signaling Technology</td>
<td>primary</td>
<td>polyclonal</td>
</tr>
<tr>
<td>Antibody Description</td>
<td>Species</td>
<td>Dilution</td>
<td>Supplier</td>
<td>Antibody Type</td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-----------</td>
<td>----------</td>
<td>---------------------------</td>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td>Anti-cyclin D1</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signaling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>monoclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-phospho-p38MAPK (Thr180/Tyr182)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signaling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>monoclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-p38MAPK (total)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signaling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>monoclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-phospho-mTOR (Ser2448)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signalling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>polyclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-mTOR (total)</td>
<td>rabbit</td>
<td>1:2 000</td>
<td>Cell Signalling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>polyclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-phospho-tuberin (Thr1462)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signalling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>polyclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-phospho-tuberin (Ser939)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signalling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>polyclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-tuberin (total)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signalling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>polyclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-phospho-S6K (Thr389)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signalling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>polyclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-S6K (total)</td>
<td>rabbit</td>
<td>1:1 000</td>
<td>Cell Signalling Technology</td>
<td>primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>polyclonal</td>
<td></td>
</tr>
<tr>
<td>Antibody</td>
<td>Species</td>
<td>Dilution</td>
<td>Company</td>
<td>Type</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>---------</td>
<td>----------</td>
<td>---------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>Anti-β-actin</td>
<td>mouse</td>
<td>1:5 000</td>
<td>Abcam, Cambridge, UK</td>
<td>primary monoclonal</td>
<td></td>
</tr>
<tr>
<td>Anti-rabbit IRDye_800</td>
<td>goat</td>
<td>1:2 000</td>
<td>LI-COR Biosciences, Cambridge, UK</td>
<td>secondary -</td>
<td></td>
</tr>
<tr>
<td>Anti-mouse IRDye_680</td>
<td>goat</td>
<td>1:10 000</td>
<td>LI-COR Biosciences</td>
<td>secondary -</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1.

A. Ratio pSer217/221 MEK1/2/β-actin

B. Ratio total MEK1/2/β-actin

C. Ratio pSer217/221 MEK1/2/total MEK1/2
Figure 2.

**Ratio pThr183 ERK1/2/β-actin**

![Graph A showing Ratio pThr183 ERK1/2/β-actin with bars for Control, PRL-oma, ACTH-oma, GH-oma, NFPA, and statistical significance symbols.]

**Ratio total ERK1/2/β-actin**

![Graph B showing Ratio total ERK1/2/β-actin with bars for Control, PRL-oma, ACTH-oma, GH-oma, NFPA.]

**Ratio pThr183 ERK1/2/total ERK1/2**

![Graph C showing Ratio pThr183 ERK1/2/total ERK1/2 with bars for Control, PRL-oma, ACTH-oma, GH-oma, NFPA, and statistical significance symbols.]


Figure 3.

**Ratio pSer62/Thr58 c-MYC/β-actin**

![Graph A showing % of control for Control, PRL-oma, ACTH-oma, GH-oma, and NFPA with significant differences marked by **.]

**Ratio total c-MYC/β-actin**

![Graph B showing % of control for Control, PRL-oma, ACTH-oma, GH-oma, and NFPA.]

**Ratio pSer62/Thr58 c-MYC/total c-MYC**

![Graph C showing % of control for Control, PRL-oma, ACTH-oma, GH-oma, and NFPA with significant differences marked by **.]

B-Raf/MEK/ERK and PI3K/Akt/mTOR in pituitary adenomas
Figure 4.

**Ratio CYCLIN D1/β-actin**

![Graph showing the ratio of CYCLIN D1/β-actin in different conditions](image)

- Control
- PRL-oma
- ACTH-oma
- GH-oma
- NFPA

% of control
Figure 5.

A. pMEK1/2 44, 45 kDa
   tMEK 1/2 44, 45 kDa
   β-actin 42 kDa

   Normal | PRL | ACTH | GH | NFPA

B. pERK1/2 42, 44 kDa
   tERK 1/2 42, 44 kDa
   β-actin 42 kDa

   Normal | PRL | ACTH | GH | NFPA

C. pc-MYC 57-70 kDa
   c-MYC 57-70 kDa
   β-actin 42 kDa

   Normal | PRL | ACTH | GH | NFPA

D. CYCLIN D1 36 kDa
   β-actin 42 kDa

   Normal | PRL | ACTH | GH | NFPA
1. Figure 6.

**MEK1, MEK2, ERK1, ERK2, c-MYC, CCND1/β-Actin**

![Graph showing expression levels of various proteins](image)

- **Control**
- **NFPA**

% of control

- MEK1
- MEK2
- ERK1
- ERK2
- c-MYC
- CCND1